Advanced Enzyme Technologies Announces Strong Financial Results for Q4 and FY Ended March 2026
Advanced Enzyme Technologies Limited, a specialty biotech company, today announced its audited financial results for the fourth quarter and the full year ended March 2026. The company, a global leader in manufacturing enzymes and probiotics, reported significant growth across key financial and operational segments.Consolidated Financial Highlights
The company's performance metrics for the financial year ending March 2026 show robust year-over-year growth. The consolidated financial data is summarized below:| (Amount in INR Mn.) | Q4 FY26 | Q3 FY26 | Q4 FY25 | Change (Y-o-Y %) | FY26 | FY25 | Change (%) |
|---|---|---|---|---|---|---|---|
| Revenue | 2,034 | 1,719 | 1,672 | +22% | 7,458 | 6,369 | +17% |
| EBITDA | 632 | 494 | 456 | +39% | 2,291 | 1,944 | +18% |
| EBITDA Margin (%) | 31% | 29% | 27% | 31% | 31% | ||
| PAT | 453 | 432 | 267 | +69% | 1,736 | 1,340 | +30% |
| PAT Margin (%) | 22% | 25% | 16% | 23% | 21% | ||
| EPS | 3.84 | 3.80 | 2.37 | +62% | 15.08 | 11.72 | +29% |
Key Financial Performance Review (Year-over-Year)
On a year-over-year basis, the company reported a substantial increase in revenue and profits.- Revenue: Revenue from operations on a consolidated basis reached ₹2,034 million in Q4 FY26, up from ₹1,672 million in Q4 FY25, marking a 22% growth.
- Profitability: Consolidated EBITDA for Q4 FY26 stood at ₹632 million, significantly up from ₹456 million in Q4 FY25, representing a 39% increase. Profit before tax was ₹598 million in Q4 FY26, compared to ₹435 million in Q4 FY25.
- PAT and EPS: Profit after tax grew by 69%, totaling ₹453 million in Q4 FY26 (up from ₹267 million in Q4 FY25). Earnings Per Share (EPS) for the quarter was ₹3.84, compared to ₹2.37 in the same period last year.
Operational Highlights
Segmental Revenue Growth
Analysis of the operational segments reveals strong growth across key areas:| Segment | Q4 FY26 (INR Mn.) | Q4 FY25 (INR Mn.) | Change (%) |
|---|---|---|---|
| Human Nutrition | 1,281 | 1,031 | +24% |
| Animal Nutrition | 250 | 209 | +19% |
| Bio-Processing | 324 | 278 | +17% |
| Specialized Manufacturing | 180 | 154 | +17% |
The Human Nutrition segment led growth, increasing by 24% to ₹1,281 million in Q4 FY26, driven by increased activity in the Pharma/API and Bio-catalysis business. Similarly, the Animal Nutrition segment grew by 19% to ₹250 million.
Geographical Revenue Contributions
The geographical breakdown also showed strong performance:| Metric | Q4 FY26 (INR Mn.) | Q4 FY25 (INR Mn.) | Change (%) |
|---|---|---|---|
| Domestic Sales | 1,061 | 704 | +51% |
| International Sales | 973 | 968 | +1% |
Total domestic sales accounted for ₹1,061 million in Q4 FY26, a significant increase of 51% from ₹704 million in Q4 FY25. International sales, while showing only a marginal 1% increase on a year-over-year basis, included strong growth from Asia (ex-India) and the rest of the world.
Quarter-over-Quarter Performance
Reviewing the quarter-over-quarter movement, the consolidated revenue increased to ₹2,034 million in Q4 FY26 from ₹1,719 million in Q3 FY26, an 18% growth. EBITDA rose by 28% to ₹632 million during Q4 FY26, up from ₹494 million in Q3 FY26.The Human Nutrition segment demonstrated particularly strong sequential growth, increasing by 33% to ₹1,281 million in Q4 FY26 compared to ₹960 million in Q3 FY26.
Operational Growth and Future Focus
The company remains focused on strengthening its business model across its three core segments: Human Nutrition, Animal Nutrition, and Bio-Processing.- Human Nutrition: The company is actively replicating its successful B2C model from the USA into India. It has launched its own nutraceutical brand, Wellfa, offering products for various health needs, including gut health, immunity support, and weight management. This segment is anticipated to be a key growth driver.
- Animal Nutrition: Efforts are focused on developing innovative nutritional products for animal feeds, aiming to enhance performance. The company also plans to expand its sales and marketing teams across the USA, MENA, and Asian regions, while broadening its global presence through new distributors.
- Bio-Processing and Bio-catalysis: In the Bio-Processing segment, the Food business contributed notably, with the overall segment showing growth of 17% in Q4 FY26. In the specialized area of Biocatalysis, the company is developing enzymatic solutions for API manufacturers, aiming to reduce energy consumption and processing time.
Furthermore, the company continues to invest in its R&D infrastructure and its product portfolio, with a focus on expanding its presence in the baking industry and submitting dossiers to global safety authorities. The company also maintains a history of inorganic growth, having completed four acquisitions over the past nine years, financed through internal accruals.
ADVENZYMES Stock Price Movement
On Friday, Advanced Enzyme Technologies Limited shares edged higher, closing at ₹357.25 after gaining 0.53% for the session. Trading saw a solid volume of 421,044 shares, with the equity's year-high mark at ₹372 remaining a key focus for investors.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.